125 related articles for article (PubMed ID: 19351776)
1. The impact of HER2/neu expression level on response to the E75 vaccine: from U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
Benavides LC; Gates JD; Carmichael MG; Patil R; Holmes JP; Hueman MT; Mittendorf EA; Craig D; Stojadinovic A; Ponniah S; Peoples GE
Clin Cancer Res; 2009 Apr; 15(8):2895-904. PubMed ID: 19351776
[TBL] [Abstract][Full Text] [Related]
2. Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
Amin A; Benavides LC; Holmes JP; Gates JD; Carmichael MG; Hueman MT; Mittendorf EA; Storrer CE; Jama YH; Craig D; Stojadinovic A; Ponniah S; Peoples GE
Cancer Immunol Immunother; 2008 Dec; 57(12):1817-25. PubMed ID: 18392824
[TBL] [Abstract][Full Text] [Related]
3. The E75 HER2/neu peptide vaccine.
Mittendorf EA; Holmes JP; Ponniah S; Peoples GE
Cancer Immunol Immunother; 2008 Oct; 57(10):1511-21. PubMed ID: 18536917
[TBL] [Abstract][Full Text] [Related]
4. Analysis of naïve and memory CD4 and CD8 T cell populations in breast cancer patients receiving a HER2/neu peptide (E75) and GM-CSF vaccine.
Hueman MT; Stojadinovic A; Storrer CE; Dehqanzada ZA; Gurney JM; Shriver CD; Ponniah S; Peoples GE
Cancer Immunol Immunother; 2007 Feb; 56(2):135-46. PubMed ID: 16783576
[TBL] [Abstract][Full Text] [Related]
5. HER2/neu-based vaccination with li-Key hybrid, GM-CSF immunoadjuvant and trastuzumab as a potent triple-negative breast cancer treatment.
Zhou Y
J Cancer Res Clin Oncol; 2023 Aug; 149(9):6711-6718. PubMed ID: 36692548
[TBL] [Abstract][Full Text] [Related]
6. Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission.
Chu CS; Boyer J; Schullery DS; Gimotty PA; Gamerman V; Bender J; Levine BL; Coukos G; Rubin SC; Morgan MA; Vonderheide RH; June CH
Cancer Immunol Immunother; 2012 May; 61(5):629-41. PubMed ID: 22021066
[TBL] [Abstract][Full Text] [Related]
7. Breast Cancer Vaccines: Disappointing or Promising?
Zhu SY; Yu KD
Front Immunol; 2022; 13():828386. PubMed ID: 35154149
[TBL] [Abstract][Full Text] [Related]
8. Restoring anti-oncodriver Th1 responses with dendritic cell vaccines in HER2/neu-positive breast cancer: progress and potential.
De La Cruz LM; Nocera NF; Czerniecki BJ
Immunotherapy; 2016 Oct; 8(10):1219-32. PubMed ID: 27605070
[TBL] [Abstract][Full Text] [Related]
9. Clinical Development of the E75 Vaccine in Breast Cancer.
Clifton GT; Gall V; Peoples GE; Mittendorf EA
Breast Care (Basel); 2016 Apr; 11(2):116-21. PubMed ID: 27239173
[TBL] [Abstract][Full Text] [Related]
10. A pilot study in prostate cancer patients treated with the AE37 Ii-key-HER-2/neu polypeptide vaccine suggests that HLA-A*24 and HLA-DRB1*11 alleles may be prognostic and predictive biomarkers for clinical benefit.
Anastasopoulou EA; Voutsas IF; Keramitsoglou T; Gouttefangeas C; Kalbacher H; Thanos A; Papamichail M; Perez SA; Baxevanis CN
Cancer Immunol Immunother; 2015 Sep; 64(9):1123-36. PubMed ID: 26026288
[TBL] [Abstract][Full Text] [Related]
11. Preclinical and Clinical Observations Implying Combination Therapy to Enhance the Efficacy of the Her-2/neu B-Cell Peptide-Based Vaccine HER-Vaxx and to Prevent Immune Evasion.
Tobias J; Högler S; Raigel M; Lin DS; Chao Y; Kenner L; Garner-Spitzer E; Yavrom S; Ede NJ; Zielinski CC; Kundi M; Wiedermann U
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203458
[TBL] [Abstract][Full Text] [Related]
12. AE37 peptide vaccination in prostate cancer: identification of biomarkers in the context of prognosis and prediction.
Perez SA; Anastasopoulou EA; Papamichail M; Baxevanis CN
Cancer Immunol Immunother; 2014 Nov; 63(11):1141-50. PubMed ID: 25052849
[TBL] [Abstract][Full Text] [Related]
13. Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
Mittendorf EA; Clifton GT; Holmes JP; Clive KS; Patil R; Benavides LC; Gates JD; Sears AK; Stojadinovic A; Ponniah S; Peoples GE
Cancer; 2012 May; 118(10):2594-602. PubMed ID: 21989902
[TBL] [Abstract][Full Text] [Related]
14. Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer.
Disis ML; Wallace DR; Gooley TA; Dang Y; Slota M; Lu H; Coveler AL; Childs JS; Higgins DM; Fintak PA; dela Rosa C; Tietje K; Link J; Waisman J; Salazar LG
J Clin Oncol; 2009 Oct; 27(28):4685-92. PubMed ID: 19720923
[TBL] [Abstract][Full Text] [Related]
15. Clinical and immunologic responses of HLA-A3+ breast cancer patients vaccinated with the HER2/neu-derived peptide vaccine, E75, in a phase I/II clinical trial.
Patil R; Clifton GT; Holmes JP; Amin A; Carmichael MG; Gates JD; Benavides LH; Hueman MT; Ponniah S; Peoples GE
J Am Coll Surg; 2010 Feb; 210(2):140-7. PubMed ID: 20113933
[TBL] [Abstract][Full Text] [Related]
16. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.
Slamon DJ; Clark GM; Wong SG; Levin WJ; Ullrich A; McGuire WL
Science; 1987 Jan; 235(4785):177-82. PubMed ID: 3798106
[TBL] [Abstract][Full Text] [Related]
17. Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients.
Mittendorf EA; Clifton GT; Holmes JP; Schneble E; van Echo D; Ponniah S; Peoples GE
Ann Oncol; 2014 Sep; 25(9):1735-1742. PubMed ID: 24907636
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of a Dual-Epitope Dendritic Cell Vaccine as Part of Combined Immunotherapy for HER2-Expressing Breast Tumors.
Vincent BG; File DM; McKinnon KP; Moore DT; Frelinger JA; Collins EJ; Ibrahim JG; Bixby L; Reisdorf S; Laurie SJ; Park YA; Anders CK; Collichio FA; Muss HB; Carey LA; van Deventer HW; Dees EC; Serody JS
J Immunol; 2023 Jul; 211(2):219-228. PubMed ID: 37204246
[TBL] [Abstract][Full Text] [Related]
19. Can Patients with HER2-Low Breast Cancer Benefit from Anti-HER2 Therapies? A Review.
Wang J; Liao D; Zhang X; Miao C; Chen K
Breast Cancer (Dove Med Press); 2023; 15():281-294. PubMed ID: 37113514
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
